Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Telavancin in the Treatment of Concurrent Staphylococcus aureus Bacteremia: A Retrospective Analysis of ATLAS and ATTAIN Studies.

Wilson SE, Graham DR, Wang W, Bruss JB, Castaneda-Ruiz B.

Infect Dis Ther. 2017 Sep;6(3):413-422. doi: 10.1007/s40121-017-0162-1. Epub 2017 Jul 10.

2.

Source control review in clinical trials of anti-infective agents in complicated intra-abdominal infections.

Solomkin JS, Ristagno RL, Das AF, Cone JB, Wilson SE, Rotstein OD, Murphy BS, Severin KS, Bruss JB.

Clin Infect Dis. 2013 Jun;56(12):1765-73. doi: 10.1093/cid/cit128. Epub 2013 Mar 5. Review.

PMID:
23463643
3.

Pharmacokinetics and safety of single and multiple doses of ACHN-490 injection administered intravenously in healthy subjects.

Cass RT, Brooks CD, Havrilla NA, Tack KJ, Borin MT, Young D, Bruss JB.

Antimicrob Agents Chemother. 2011 Dec;55(12):5874-80. doi: 10.1128/AAC.00624-11. Epub 2011 Sep 12.

4.

Lack of evidence associating nephrotoxicity with low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis.

Bruss JB.

Clin Infect Dis. 2009 Sep 1;49(5):806; author reply 807-8. doi: 10.1086/605287. No abstract available.

PMID:
19653850
5.

A double-blind, placebo-controlled trial of oral human immunoglobulin for gastrointestinal dysfunction in children with autistic disorder.

Handen BL, Melmed RD, Hansen RL, Aman MG, Burnham DL, Bruss JB, McDougle CJ.

J Autism Dev Disord. 2009 May;39(5):796-805. doi: 10.1007/s10803-008-0687-y. Epub 2009 Jan 16.

PMID:
19148734
6.

The economics of pediatric formulation development for off-patent drugs.

Milne CP, Bruss JB.

Clin Ther. 2008 Nov;30(11):2133-45. doi: 10.1016/j.clinthera.2008.11.019. Review.

PMID:
19108801
7.

Impact of ontogeny on linezolid disposition in neonates and infants.

Kearns GL, Jungbluth GL, Abdel-Rahman SM, Hopkins NK, Welshman IR, Grzebyk RP, Bruss JB, Van Den Anker JN; Pediatric Pharmacology Research Unit Network.

Clin Pharmacol Ther. 2003 Nov;74(5):413-22.

PMID:
14586382
8.

Safety and tolerability of linezolid in children.

Saiman L, Goldfarb J, Kaplan SA, Wible K, Edge-Padbury B, Naberhuis-Stehouwer S, Bruss JB.

Pediatr Infect Dis J. 2003 Sep;22(9 Suppl):S193-200.

PMID:
14520146
9.

Hematologic effects of linezolid in young children.

Meissner HC, Townsend T, Wenman W, Kaplan SL, Morfin MR, Edge-Padbury B, Naberhuis-Stehouwer S, Bruss JB.

Pediatr Infect Dis J. 2003 Sep;22(9 Suppl):S186-92.

PMID:
14520145
10.

Linezolid for the treatment of methicillin-resistant Staphylococcus aureus infections in children.

Kaplan SL, Afghani B, Lopez P, Wu E, Fleishaker D, Edge-Padbury B, Naberhuis-Stehouwer S, Bruss JB.

Pediatr Infect Dis J. 2003 Sep;22(9 Suppl):S178-85.

PMID:
14520144
11.

Linezolid for the treatment of complicated skin and skin structure infections in children.

Yogev R, Patterson LE, Kaplan SL, Adler S, Morfin MR, Martin A, Edge-Padbury B, Naberhuis-Stehouwer S, Bruss JB.

Pediatr Infect Dis J. 2003 Sep;22(9 Suppl):S172-7.

PMID:
14520143
12.

Linezolid for the treatment of children with bacteremia or nosocomial pneumonia caused by resistant gram-positive bacterial pathogens.

Jantausch BA, Deville J, Adler S, Morfin MR, Lopez P, Edge-Padbury B, Naberhuis-Stehouwer S, Bruss JB.

Pediatr Infect Dis J. 2003 Sep;22(9 Suppl):S164-71.

PMID:
14520142
13.

Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates.

Deville JG, Adler S, Azimi PH, Jantausch BA, Morfin MR, Beltran S, Edge-Padbury B, Naberhuis-Stehouwer S, Bruss JB.

Pediatr Infect Dis J. 2003 Sep;22(9 Suppl):S158-63.

PMID:
14520141
14.

Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children.

Kaplan SL, Deville JG, Yogev R, Morfin MR, Wu E, Adler S, Edge-Padbury B, Naberhuis-Stehouwer S, Bruss JB; Linezolid Pediatric Study Group.

Pediatr Infect Dis J. 2003 Aug;22(8):677-86.

PMID:
12913766
15.

A severity score for complicated skin and soft tissue infections derived from phase III studies of linezolid.

Wilson SE, Solomkin JS, Le V, Cammarata SK, Bruss JB.

Am J Surg. 2003 Apr;185(4):369-75.

PMID:
12657392
16.

Similarity of the oral microbiota of pre-school children with that of their caregivers in a population-based study.

Tanner AC, Milgrom PM, Kent R Jr, Mokeem SA, Page RC, Liao SI, Riedy CA, Bruss JB.

Oral Microbiol Immunol. 2002 Dec;17(6):379-87. Erratum in: Oral Microbiol Immunol. 2003 Oct;18(5):338.

PMID:
12485330
17.

Hematologic effects of linezolid: summary of clinical experience.

Gerson SL, Kaplan SL, Bruss JB, Le V, Arellano FM, Hafkin B, Kuter DJ.

Antimicrob Agents Chemother. 2002 Aug;46(8):2723-6.

18.
19.

Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [(14)C]linezolid to healthy human subjects.

Slatter JG, Stalker DJ, Feenstra KL, Welshman IR, Bruss JB, Sams JP, Johnson MG, Sanders PE, Hauer MJ, Fagerness PE, Stryd RP, Peng GW, Shobe EM.

Drug Metab Dispos. 2001 Aug;29(8):1136-45.

PMID:
11454733
20.

Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections.

Stevens DL, Smith LG, Bruss JB, McConnell-Martin MA, Duvall SE, Todd WM, Hafkin B.

Antimicrob Agents Chemother. 2000 Dec;44(12):3408-13.

21.

Protective effects of pertussis immunoglobulin (P-IGIV) in the aerosol challenge model.

Bruss JB, Siber GR.

Clin Diagn Lab Immunol. 1999 Jul;6(4):464-70.

22.

Treatment of severe pertussis: a study of the safety and pharmacology of intravenous pertussis immunoglobulin.

Bruss JB, Malley R, Halperin S, Dobson S, Dhalla M, Mciver J, Siber GR.

Pediatr Infect Dis J. 1999 Jun;18(6):505-11.

PMID:
10391179

Supplemental Content

Loading ...
Support Center